Active specific T-cell-based immunotherapy for cancer: Nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects

Nadine Fernandez, Marie Thérèse Duffour, Michel Perricaudet, Michael T. Lotze, Thomas Tursz, Laurence Zitvogel

    Research output: Contribution to journalArticlepeer-review

    37 Citations (Scopus)

    Abstract

    Whereas tumor cells are poor immunogens, recombinant tumor cells or dendritic cells as well as engineered viruses have been demonstrated to elicit specific antitumor immune responses leading to tumor growth suppression and long-lasting immunity in mouse tumor models. Single cytotoxic T lymphocyte-defined epitope-based strategies have proved useful for immunization in tumor-bearing mice. This strategy is under investigation in human melanoma, along with adjuvants such as cytokines or dendritic cells. Flt3L is an in vivo dendritic-cell growth factor that offers new prospects in the field of active specific immunotherapy. These immunotherapeutic approaches are being tested in clinical trials, and may open up novel avenues for disease-free patients with poor prognostic factors.

    Original languageEnglish
    Pages (from-to)53-65
    Number of pages13
    JournalCytokines, Cellular and Molecular Therapy
    Volume4
    Issue number1
    Publication statusPublished - 1 Mar 1998

    Keywords

    • Cancer vaccines
    • Cytokine gene therapy
    • Cytotoxic T lymphocytes
    • DNA immunization
    • Flt3L
    • MHC class I restricted peptides

    Cite this